Taken together, our work suggests that targeted pharmaceutical stimulation of Bmi1 expression in aging neurons could prevent accumulation of age-associated oxidative damages, protect against apoptosis and possibly counteract the progression of neurodegenerative diseases. Here, BMI1 is linked to neurodegenerative disease.